NIH to study COVID-19 vaccination during, post pregnancy

Observational study MOMI-VAX will begin evaluating the immune responses and durability of antibodies against SARS-CoV-2 in women who receive COVID-19 vaccines during or shortly after pregnancy. Researchers also will assess vaccine safety and evaluate the transfer of vaccine-induced antibodies to infants across the placenta and through breast milk. The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), is sponsoring the study. Pregnant women with COVID-19 are more likely to be hospitalized, admitted to an intensive care unit, require mechanical ventilation, and die from the illness than their non-pregnant peers. (NIH news release, 6/23/21)